Merkur Market listed Gentian Diagnostics AS has completed a private placement raising NOK 70 million
Gentian Diagnostics AS (Gentian) has received applications from Vatne Equity AS, a company controlled by Runar Vatne and represented by Henrik Krefting, the CEO of Vatne Equity AS, along with Norron AB to each subscribe for 699,814 new shares, in total 1,399,628 new shares in Gentian at a subscription price of NOK 50.00 per New Share, totalling approximately NOK 70 million.
The funds from the transaction will provide Gentian with financial flexibility to pursue various strategic alternatives, and will also be used for general corporate purposes.
Aabø-Evensen & Co AS has acted as legal advisor to Gentian in connection with the transaction.
Click here to be redirected to the Stock Exchange Notice published 15 June 2018.